A Phase 1 Study Comparing AVP-786 With AVP-923

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare pharmacokinetics (PK) of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) to AVP-923 (dextromethorphan hydrobromide [DM]/Q) at steady state.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Avanir Pharmaceuticals
• Treatments: Dextromethorphan; Quinidine; Quinidine gluconate

Criteria

Inclusion Criteria:

• Healthy adult males or females

• 18 - 60 years of age

• BMI 18 - 32 kg/m2

Exclusion Criteria:

• History or presence of significant disease

• History of substance abuse and/or alcohol abuse with the past 2 years

• Use of tobacco-containing or nicotine-containing products within 6 months

• Use of any prescription or the over-the-counter medications within 14 days